COA Requirements for 3-Bromo-2-Methylpyridine Bulk Supply: Ensuring Industrial Purity and Regulatory Compliance
- COAs for 3-bromo-2-methylpyridine must include GC purity ≥98.5%, residual solvent analysis, and heavy metal limits to meet ICH Q3 guidelines.
- Global regulatory alignment (USP, EP, ChP) requires detailed impurity profiling of related substances like 3-bromo-picoline and 2-methyl-3-bromopyridine isomers.
- NINGBO INNO PHARMCHEM CO.,LTD. provides fully traceable COAs with batch-specific data, supporting seamless customs clearance and GMP audits.
When sourcing high-purity bulk price commitments for 3-Bromo-2-methylpyridine (CAS 38749-79-0), buyers in the pharmaceutical, agrochemical, and advanced materials sectors demand more than just competitive pricing—they require ironclad quality assurance through comprehensive Certificates of Analysis (COA). Also known as 3-bromo-2-picoline or 2-methyl-3-bromopyridine, this versatile heterocyclic building block is integral to cross-coupling reactions and targeted molecular syntheses. As such, its COA must reflect stringent analytical rigor to ensure batch-to-batch consistency and regulatory acceptability worldwide.
Essential Analytical Data in Certificates of Analysis (COA)
A robust COA for 3-Bromo-2-methylpyridine must go beyond basic identity confirmation. Leading global manufacturers like NINGBO INNO PHARMCHEM CO.,LTD. issue COAs that include:
- Identity verification via FTIR and/or 1H NMR spectroscopy
- Assay purity by Gas Chromatography (GC) or HPLC, typically ≥98.5%
- Residual solvents quantified per ICH Q3C (e.g., toluene, DMF, dichloromethane)
- Heavy metals (Pb, As, Cd, Hg) below 10 ppm as per USP <231> or EP 2.4.8
- Water content by Karl Fischer titration (typically ≤0.5%)
- Appearance and physical state (colorless to pale yellow liquid)
Crucially, the COA must reference the exact lot number and catalog number, enabling full traceability from synthesis route to final shipment. This level of documentation is non-negotiable for clients developing anti-inflammatory agents, ADC-related payloads, or novel fungicides where impurity profiles directly impact biological activity and safety.
GC Purity Verification and Impurity Profiling for Pharmaceutical Use
In pharmaceutical applications—particularly in JAK/STAT or PI3K/Akt/mTOR pathway modulators—the presence of structurally similar impurities can derail clinical outcomes. The COA must therefore include a detailed impurity profile identifying and quantifying key related substances such as:
- 2-Bromo-3-methylpyridine (regioisomer)
- 3,2-Dibromomethylpyridine (over-bromination byproduct)
- Unreacted 2-methylpyridine (starting material)
- 3-Bromo-picoline oxidation products
At NINGBO INNO PHARMCHEM CO.,LTD., our optimized manufacturing process minimizes these impurities at source, ensuring that 2-Me-3-bromopyridine batches consistently achieve GC purity levels of 99.0% or higher. Each COA includes a chromatogram with retention times and peak area percentages, allowing customers to validate suitability for sensitive syntheses like Suzuki-Miyaura or Buchwald-Hartwig couplings without additional purification.
Typical COA Specifications for 3-Bromo-2-Methylpyridine (Industrial Grade)
| Parameter | Specification | Test Method |
|---|---|---|
| Chemical Name | 3-Bromo-2-methylpyridine (3-bromo-2-picoline) | IUPAC / CAS 38749-79-0 |
| Assay (GC) | ≥98.5% | GC-FID, DB-5 column |
| Appearance | Colorless to pale yellow clear liquid | Visual inspection |
| Water Content | ≤0.5% | Karl Fischer |
| Residual Solvents | Complies with ICH Q3C Class 2/3 limits | GC-Headspace |
| Heavy Metals | ≤10 ppm | ICP-MS / USP <231> |
| Related Substances | Any single impurity ≤0.3%; total impurities ≤1.0% | HPLC-UV |
Regulatory Compliance: COA Standards Across US, EU, and APAC Markets
Global supply chains demand harmonized documentation. A compliant COA for 3-bromo-2-methylpyridine must align with pharmacopeial standards across key regions:
- United States: Meets USP general chapters on organic impurities and elemental impurities (USP <467>, <232>/<233>)
- European Union: Complies with Ph. Eur. monographs for pyridine derivatives and ICH Q3A(R2)/Q3B(R2)
- Asia-Pacific: Aligns with Chinese Pharmacopoeia (ChP) and Japanese PMDA requirements for synthetic intermediates
Additionally, Certificates of Origin (COO) are often required alongside the COA for customs clearance—confirming that the product is synthetically derived and manufactured in China under ISO 9001-certified conditions. NINGBO INNO PHARMCHEM CO.,LTD. integrates COO and COA workflows to eliminate documentation delays, ensuring uninterrupted supply for bulk orders used in material science or agricultural chemical R&D.
For industries relying on 2-methyl-3-bromopyridine as a cornerstone intermediate—from PROTAC degraders to crop protection actives—the COA is not merely a quality document but a regulatory passport. Only manufacturers with vertically integrated synthesis routes, rigorous QC protocols, and global compliance expertise can deliver the consistency required at scale.
As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. guarantees COA transparency, industrial purity, and on-time bulk delivery—making us the trusted partner for high-stakes organic synthesis worldwide.